OSUMMER.12 Mouse NRAS-Mutant Melanoma Cell Line

Each vial contains >1X10⁶ viable cells.

Cells are tested negative for infectious diseases by a Mouse Essential CLEAR Panel by Charles River Animal Diagnostic Services.

Cells are verified to be of mouse origin and negative for interspecies contamination from rat, human, chinese hamster, Golden Syrian hamster, and nonhuman Primate (NHP) as assessed by a Contamination Clear panel by Charles River Animal Diagnostic Services

Cells are negative for mycoplasma contamination.

Melanoma skin cancer develops from melanocytes, a cell type found in the skin that is involved in melanin production and that influences pigmentation. While skin cancers are the most common type of cancers, melanoma is less common, accounting for only about 1% of skin cancer cases. Melanoma is nonetheless a significant form of skin cancer due to its capability to metastasize to other tissues if not detected in early stages. Early-stage melanoma can be cured by resection, but fewer treatment options are available for patients with metastatic disease. Development of resistance to targeted and immunotherapies, as well as toxicity are major problems. Along with sun exposure, sporadic genetic mutations have been associated with melanomas. Immunotherapy treatments targeting these genes or pathways have been proven to have significant benefits in melanoma patients by improving general response and survival.
These NRAS-Mutant cell lines can be used to discover and address potential immunotherapies in NRAS-mutant human melanomas which make up an estimated 15-25% of human melanomas. These cell lines also enable in vivo testing of immunotherapies with a mouse model.
OSUMMER.12 NRAS mouse melanoma cell line was derived from a female TN mouse exposed to UVA and UVB radiation. OSUMMER.12 carries the specific NRAS mutation Q61R. WES revealed high SNV (Single Nucleotide Variants) and low CNA (Copy Number Alterations) burden, as well as the presence of UV signature mutations.

Source
OSUMMER.12 was derived from melanoma induced in TN (Tyr::CreER) mice exposed to UVA or UVB radiation on postnatal day 3.

References
1.Nat Rev Dis Primers 2015, 1: 15003.
2.Lancet 2018, 392(10151): 971-984.
3.Life Sci Alliance 2021, 4(9): e202101135.

The OSUMMER cell lines are responsive to immunotherapy treatments. These NRAS-Mutant cell lines can be used to discover and address potential immunotherapies in NRAS-mutant human melanomas which make up an estimated 15-25% of human melanomas. These cell lines also enable in vivo testing of immunotherapies with a mouse model. OSUMMER.12 carries the specific NRAS mutation Q61R and can form tumors in vivo without Matrigel injection.

OSUMMER.12 cells should be stored in liquid nitrogen until use. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.

Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/restrictedcelluse. This product may not be: re-engineered or copied; used to make derivatives, modifications or functional equivalents; used to obtain patents or other IP claiming use of the product; used to develop, test, or manufacturer a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact licensing@milliporesigma.com.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.